Innate Pursues Anti-Leukemic In EU
Lumoxiti Potentially Transformative For French Firm
Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.
You may also be interested in...
The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.
The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?
Celgene is paying AstraZeneca $450m up front in order to develop the UK drug maker's anti-PD-L1 product MEDI4736 in a range of blood cancers – a partnership Celgene thinks could be a "meaningful" driver of growth past 2020.